FRESENIUS KABI Compound α-keto Acid For Chronic Renal Insufficiency 100 Tablets

(No reviews yet) Write a Review
US $59.99
SKU:
BV004
Shipping:
Calculated at Checkout
Origin:
China
Form:
Tablets
Adding to cart… The item has been added

Product Overview

Common name: Compound α-keto acid tablets
English name: Compound α-Ketoacid Tablets
Product name: Kaitong
Ingredients: This product is a compound preparation, containing 4 kinds of calcium keto amino acid, 1 kind of calcium hydroxy amino acid and 5 kinds of amino acid. Its components are: racemic ketone isoleucine calcium 67mg, ketoleucine calcium 101mg, ketophenylalanine calcium 68mg, ketovaline calcium 86mg, racemic hydroxymethionine calcium 59mg, lysine acetic acid 105mg, Threonine 53mg, tryptophan 23mg, histidine 38mg, tyrosine 30mg.
Properties: This product is a yellow film-coated tablet, which is white after removing the film coat.
Indications of function: In conjunction with a low-protein diet, prevention and treatment of damage caused by imbalance of protein metabolism caused by chronic renal insufficiency. Usually used for patients with glomerular filtration rate less than 25 ml per minute. A low-protein diet requires an adult’s daily protein intake of 40 grams or less.
Specification: 0.63g*100 pieces/box
Usage and dosage: Oral. 3 to 4 times a day, 4 to 8 tablets at a time, during the meal, swallow the whole tablet. Follow your doctor's advice when necessary. This dose is calculated based on the adult body weight of 70kg. For patients with a glomerular filtration rate of less than 25 ml per minute, this product can be taken for a long time with a low-protein diet that does not exceed 40 grams (adult) per day.
Adverse reactions: Hypercalcemia may occur. If hypercalcemia occurs, it is recommended to reduce vitamin D intake. If hypercalcemia continues to occur, reduce the amount of this product and reduce the intake of other calcium-containing substances.
Contraindication: Hypercalcemia and disorders of amino acid metabolism. When using this product in patients with hereditary phenylketonuria, it must be noted that this product contains phenylalanine.
Matters needing attention: This product should be taken during meals to make it fully absorbed and converted into the corresponding amino acids. Blood calcium levels should be regularly monitored and sufficient calories should be taken.
Drug interactions: Simultaneous use with other calcium-containing drugs can increase blood calcium levels. When taking this product for treatment in patients with uremia, if using aluminum hydroxide drugs at the same time, it is necessary to reduce the amount of aluminum hydroxide. Note the drop in blood phosphorus levels. In order not to affect the absorption of drugs, drugs that combine with calcium to form insoluble complexes (such as: tetracycline, quinolones such as ciprofloxacin and norfloxacin, iron, fluoride and drugs containing estramustine, etc.), It should not be taken at the same time as Kaitong. The interval between taking these medicines and Kaitong is at least 2 hours. Increased blood calcium can increase the sensitivity of cardiac glycoside drugs and therefore also increase the risk of arrhythmia.
Pharmacology and Toxicology: This product can provide essential amino acids and minimize the intake of amino nitrogen. Ketones or hydroxy amino acids themselves do not contain amino groups, and they are converted to amino acids by using nitrogen from non-essential amino acids, which can reduce urea synthesis and the accumulation of uremic toxic products. Ketones or hydroxyamino acids do not cause ultrafiltration of the remaining nephrons, and can improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy. This product is combined with a low-protein diet to reduce the intake of nitrogen, and at the same time avoid the adverse consequences caused by insufficient protein intake and malnutrition.
Storage: Store below 25â„?in a dry place.
Packing: Aluminum plastic packaging, 100 pieces/box.
Validity: 36 months
Executive standard: YBH14982004
Approval number: National Pharmaceutical Standard H20041442
Business Name: Beijing Fresenius Kabi Pharmaceutical Co., Ltd.

Reviews

(No reviews yet) Write a Review